Association between biomarkers and house dust mite sublingual immunotherapy in allergic asthma.

Abstract

House dust mite (HDM) sublingual immunotherapy (SLIT) has demonstrated efficacy in clinical trials of patients with asthma. Airway inflammation is a characteristic of respiratory allergy, but its relationship to SLIT remains unclear. We evaluate the association between clinical outcomes with pulmonary function and biomarkers in before and after HDM SLIT (UMIN Number 000022390). One hundred twelve patients with asthma sensitized to HDM were randomized to add-on 6 standardized quality (SQ)-HDM SLIT to pharmacotherapy or pharmacotherapy alone for 48weeks. At baseline and end of study, biomarkers, blood eosinophils, serum IgE, serum periostin, fractional exhaled nitric oxide (FeNO), and spirometry and clinical symptoms were measured. Association between biomarkers and an increase in FEV1 of 120mL or greater were analysed. Sublingual immunotherapy (SLIT) demonstrated a significant reduction of serum periostin (P<.001), FeNO (P<.01), and increase in HDM-specific IgE (P<.05), FEV1 (P<.001) and improvement of clinical symptom scores, when compared to pharmacotherapy. The change in FEV1 correlated with the changes in serum periostin (r=.696, P<.001) and the changes in FeNO (r=.682, P<.001). The independent predictor of improvement in airflow limitation was changed in serum periostin (r2 =.753, P=.013) and FeNO (P=.038). Based on cut-off values derived by receiver operating characteristic analysis (periostin 30.9ng/mL, FeNO 28.0ppb), patients were distinguished responders from non-responders, but with no predictive value for blood eosinophils or total IgE. The proportion of patients with both high periostin and FeNO levels was significantly higher in responder than in non-responder (P=.026). Adding HDM SLIT to pharmacotherapy resulted in reduced serum periostin and FeNO, and improved pulmonary function. Serum periostin and FeNO may be useful biomarkers for prediction of SLIT.